---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-023958"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:57:30.296166+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics extends working capital loan maturity to Sept 2027 or earlier tied to convertible notes

## Summary
- Extended maturity to earlier of Sept 1, 2027, or (if 1.5% convertible notes remain) May 12, 2026.
- If note maturity extended beyond Aug 11, 2026, loan due 91 days prior to that extended date.
- Amendment with Hercules Capital, Inc. as agent and lender, dated Feb 13, 2025.
- Borrower reaffirms security grant and releases claims against lender as part of agreement.
- No changes to other terms; conditions precedent include representations and no default.

## SEC filing metadata
- accession: 0000950170-25-023958
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017025023958/0000950170-25-023958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017025023958/hrtx-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-023958
- JSON: https://secwatch.observer/filing/0000950170-25-023958.json
- Plain text: https://secwatch.observer/filing/0000950170-25-023958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.